1. Home
  2. MDCX vs NEUP Comparison

MDCX vs NEUP Comparison

Compare MDCX & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Medicus Pharma Ltd.

MDCX

Medicus Pharma Ltd.

N/A

Current Price

$0.48

Market Cap

26.2M

Sector

N/A

ML Signal

N/A

NEUP

Neuphoria Therapeutics Inc.

N/A

Current Price

$4.56

Market Cap

24.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
MDCX
NEUP
Founded
2008
1996
Country
United States
United States
Employees
12
8
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
26.2M
24.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MDCX
NEUP
Price
$0.48
$4.56
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
2
Target Price
$23.50
$21.00
AVG Volume (30 Days)
8.6M
54.3K
Earning Date
05-11-2026
02-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.37
$3.65
52 Week High
$8.90
$21.31

Technical Indicators

Market Signals
Indicator
MDCX
NEUP
Relative Strength Index (RSI) 31.41 52.03
Support Level $0.37 $4.01
Resistance Level $1.43 $4.56
Average True Range (ATR) 0.11 0.22
MACD -0.00 -0.02
Stochastic Oscillator 14.69 35.85

Price Performance

Historical Comparison
MDCX
NEUP

About MDCX Medicus Pharma Ltd.

Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: